Lung Deposition of Alpha1-Proteinase Inhibitor (Human) (A1-PI[H]) Inhalation Solution Using Two Inhalation Modes of the I-neb Adaptive Aerosol Delivery (AAD) System in Healthy Subjects and Subjects with Cystic Fibrosis

• Published in: Journal of aerosol medicine Vol. 29; no. 3; pp. 242 - 250
• Main Authors: Häussermann, Sabine, Winnips, Cornelis, Edelman, Jonathan, Kappeler, Dominik, Herpich, Christiane, Ehlich, Hilke, Zanker, Daniela, Kietzig, Claudius, Sommerer, Knut
• Format: Journal Article
• Language: English
• Published: United States Mary Ann Liebert, Inc 01.06.2016
• Subjects: Administration, Inhalation; Adult; Aerosols; Algorithms; alpha 1-Antitrypsin - administration & dosage; alpha 1-Antitrypsin - adverse effects; alpha 1-Antitrypsin - pharmacokinetics; Anti-Infective Agents - administration & dosage; Anti-Infective Agents - adverse effects; Anti-Infective Agents - pharmacokinetics; Anti-Inflammatory Agents - administration & dosage; Anti-Inflammatory Agents - adverse effects; Anti-Inflammatory Agents - pharmacokinetics; Cross-Over Studies; Cystic Fibrosis - drug therapy; Cystic Fibrosis - metabolism; Cystic Fibrosis - physiopathology; Drug Delivery Systems - instrumentation; Equipment Design; Female; Germany; Humans; Inhalation; Lung - drug effects; Lung - metabolism; Lung - physiopathology; Male; Models, Biological; Nebulizers and Vaporizers; Tissue Distribution; Young Adult; lung imaging; inhaled drug; lung deposition; cystic fibrosis; scintigraphy; I-neb AAD System; nebulizer; alpha1-proteinase inhibitor; alpha-1-antitrypsin; pulmonary function testing

In cystic fibrosis (CF) patients, inhalation of alpha1-proteinase inhibitor (A1-PI) can prevent or slow down persistent infections and reduce the massive ongoing inflammation and excessive levels of NE that destroy the airway epithelium, leading to progressive loss of pulmonary function and death. I...